Introduction
At least two transmitter-specific types of striatal neurons have been identified that project to the tegmental dopaminergic neurons (the majority of which are located in the ventral tegmental area and substantia nigra): a type co-containing preprotachykinin-derived neuropeptides (substance P and neurokinin A), preprodynorphinderived peptides (DYN), and y-aminobutyric acid (GABA), and a type co-containing preproenkephalin-derived neuropeptides (ENK) and GABA . The majority of striatotegmental projection neurons are of the type containing substance P (SP), DYN, and GABA (Anderson and Reiner, 1991; Reiner and Anderson, 1990) . Recent ultrastructural double-label immunohistochemical studies in rats and pigeons have demonstrated that SP-positive terminals in the ventral tegmental area (AVT) and substantia nigra (the vast majority of which are of striatal origin) synapse with both dopaminergic and non-dopaminergic tegmental neurons (Anderson and Reiner, 1991; Mendez et al., 1989; Chang, 1988; Mahalik, 1988; Kawai et al., 1987) . These anatomic data complement the results of neurochemical, behavioral, and electrophysiological studies suggesting that SP-positive striatotegmental projection neurons (which also contain DYN and GABA) regu-late the activity of dopaminergic neurons both by direct and by polysynaptic pathways (Robertson and Robertson, 1989; Reid et al., 1988; Tan and Tsou, 1988a,b; Ungerstedt and Arbuthnott, 1970) . Similarly, double-label EM immunohistochemical studies have shown that ENK-positive terminals within the AVT and substantia nigra, about 50% of which are of striatal origin (Kita and Kitai, 1986; Reiner, 1986a,b) , also contact both dopaminergic and nondopaminergic tegmental neurons (Sesack and Pickel, 1992; .
The respective roles of the two types of input to the tegmentum (SP vs ENK) are uncertain. One reason for this uncertainty is that we do not know whether the synaptic terminals from these two types of inputs segregate on separate populations of tegmental dopaminergic and non-dopaminergic neurons. To explore this issue h rther, we have developed a method for combining three distinct and readily detectable markers at the EM level with pre-embedding immunohistochemical labeling. The method developed involves the use of diaminobenzidine (DAB), benzidine dihydrochloride (BDHC), and silver-intensified immunogold (SIG) as three separate markers for immunohistochemically differentiating the localization of three antigens. Previous studies have shown how different pairs among these three markers can be used for LM and EM immunohistochemical double labeling (Anderson et al., 1991; Pickel et al., 1989; Lakos and Basbaum, 1986; Levey et al., 1986) . In the present article we describe the sequence of steps that can be used to combine all three markers for triple labeling and we show how this approach can be applied successfully to label SP-positive and ENK-positive inputs to tegmental dopaminergic and non-dop-49 aminergic neurons. We believe that other investigators may find this labeling approach of use in other instances where it is necessary to label and distinguish three separate neuronal populations or their processes at the EM level.
Materials and Methods
Perfusion and Sectioning. All methods described here follow the guidelines for care and use of laboratory animals of the University of Tennessee, which are in accordance with National Research Council guidelines. The perfusion protocol we used is a slightly modified version of that described for rats by Pickel et al. (1989) , and has been described by us in more detail previously (Anderson et al., 1991) . It should be noted, however, that this precise fixation protocol is probably not essential to the success of the EM immunohistochemical triple-labeling procedure described here; we expect that other fixatives will also be applicable to this procedure. White Carneaux pigeons (Cofambu fivia) were deeply anesthetized with chloral hydrate (7 g/kg, IP) (Sigma; St Louis, MO) and prepared for transcardial perfusion. Once the heart was exposed, pigeons were transcardially perfused with a peristaltic pump (Cole-Parmer Instrument; Niles, IL) with 20 ml heparin (1000 U/ml) in 0.75% saline, followed by 75 ml of fixative consisting of 3.5% acrolein and 2% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.2 (PB), followed by 300 ml 2% paraformaldehyde in 0.1 M PB. The perfusion should take approximately 15-20 min, which allows rapid perfusion but does not produce fluid pressures that could rupture brain blood vessels. During the period spanning the opening of the pigeon's chest and the exsanguination, the lungs were ventilated with air by a ventilator pump (Harvard Apparatus; South Natick, MA). On completion of the perfusion, the brain was removed, cut into pieces, and postfixed for 2 hr in 2% paraformaldehyde in 0.1 M PB at 4°C. The pieces were then transferred to 0.1 M PB containing 0.02% sodium azide and refrigerated overnight. The midbrain tissue blocks were cut into 40-pm sections with a vibratome and collected in 0.1 M PB the next day. We have found that this fixation procedure yields excellent EM-grade preservation of tegmentum with excellent retention of antigenicity.
Immunohistochemical Procedures. All sections were prepared for immunohistochemistry by treatment in a solution of 1% sodium borohydride in 0.1 M PB for 30 min, followed by thorough rinsing with 0.1 M PB. Sections were then incubated for 30 min at room temperature (RT) in a blocking solution consisting of 400 mg bovine albumin (BA; Sigma), 500 pl normal goat serum (NGS; Sigma), 250 pl gelatin (we recommend the gelatin provided with the gold-conjugated antiserum by Amersham, Arlington Heights, IL), and 7 mg sodium azide in 47 ml 0.01 M PBS, pH 7.4. The sections were then washed in 0.1 M PB and incubated in an antiserum cocktail containing: (a) a rat monoclonal anti-SP at a dilution of 1:250 (Accurate; Westbury, NY); (b) a rabbit polyclonal anti-leucine enkephalin (LENK) at a dilution of 1:500 (Incstar; Stillwater. MN); and (c) a mouse monoclonal anti-tyrosine hydroxylase (TH) at a dilution of 1:50 (Incstar). The anti-SP was used to label SP-positive terminals in the ventral tegmental area (AVT), the anti-LENK to label ENK-positive terminals in the AVT, and the anti-TH to label tegmental dopaminergic neurons. These antisera are highly specific, as has been demonstrated previously Reiner, 1990,1991; Reiner and Anderson, 1987; Reiner, 1986; Reiner et al., 1983; Cue110 et al., 1979 ). An incubation solution consisting of 50 mg BA (Sigma), 250 pl gelatin (provided by Amersham with the gold-conjugated antiserum), and 7 mg sodium azide in 50 ml 0.01 M PBS (pH 7.4) was used as the diluent for the primary antisera. The tissue was incubated in this primary antiserum cocktail in a microcentrifuge vial on a rotator for 2 days at 4'C and washed three times in 0.1 M PB. For the success of the method it is important to use primary antisera raised in three separate spe-cies to prevent cross-labeling. Otherwise, cross-labeling could occur due to inappropriate binding of secondaries to more than one primary during subsequent steps of the procedure .
After the rinses the sections were incubated in a secondary antiserum cocktail for 2 hr at RT. This antiserum cocktail contained three different secondary antisera: donkey anti-rat IgG (Jackson ImmunoResearch; West Grove, PA), goat anti-rabbit IgG conjugated to 1-nm gold particles (Amersham), and goat anti-mouse IgG Uackson ImmunoResearch). The secondary antisera were diluted to a 1:50 concentration with the same diluent as used for the primary antisera. After this incubation the sections were again rinsed in 0.1 M PB. Note that as part of the outcome of the step of incubating the sections in the secondary antiserum cocktail, the ENK-positive terminals were immunogold labeled. For the success of this triple-labeling method it is important to use secondary antisera raised in species other than those in which the primary antisera were raised so that the secondary antisera do not cross-bind to each other. It is also important to use affinitypurified secondary antisera (such as those available from Jackson Im-munoResearch) when primary antisera from closely related species are used (e.g., mouse vs rat) to prevent secondary antisera from binding to unintended primary antisera (for example, anti-rat secondary binding to mouse primary). The specificity of our secondary antisera was confirmed in this and in previous studies by examining ifthe secondaries cross-bound to nontarget primaries (Anderson et al., 1991) . In addition, EM examination of the tissue in this study did not reveal any profiles that were double or triple labeled, thereby further indicating the specificity of the labeling steps.
Next, the labeling steps for visualizing the SP-positive terminals were completed. The sections were first incubated for 1 hr at RT in rat peroxidase-anti-peroxidase (PAP; Jackson ImmunoResearch) diluted 1:50 in the same diluent as the primary antisera. After rinsing in 0.1 M PB, the SPpositive labeling was completed with a DAB labeling procedure as described previously Reiner, 1990,1991; Reiner et al., 1983) . In brief, the tissue was immersed for 20 min in 50 ml0.05 M cacodylate buffer containing 50 mg 3,3'-diaminobenzidine tetrahydrochloride (DAB; Sigma) and 175 mg imidazole, with the addition of 200 pI 3% H202 during the last 10 min and with continuous agitation throughout. After completion of the DAB-labeling step, the sections were washed six times in 0.1 M PB.
The next step consisted of using the chromogen benzidine dihydrochloride (BDHC) to complete the labeling of the TH-positive tegmental structures (Lakos and Basbaum, 1986; kvey et al., 1986) . The sections were incubated for 1 hr at RT in mouse PAP diluted 1:lOO in the same diluent as used previously. They were then rinsed three times for 10 min in 0.1 M PB (pH 6.8). The TH-positive labeling was visualized by immersion for 15 min in 95 ml dH20 containing 10 mg BDHC. 25 mg sodium nitroferricyanide, and 5 ml 0.2 M PB (pH 6.8), with the addition of 200 ~1 3% Hz02 during the last 5 min and with continuous agitation throughout (Levey et al., 1986) . The sections were then rinsed in 0.1 M PB (pH 6.8) and osmicated to prevent any breakdown of the BDHC reaction product. To osmicate, sections were rinsed in cacodylate buffer (pH 6.8) and immersed for 30 min in 2.0% os04 in 0.1 M cacodylate buffer (pH 6.8). then rinsed extensively in cacodylate buffer followed by 0.1 M PB (pH 7.2), and stored in 0.02% sodium azide in 0.1 M PB until silver intensification (in the case of our tissue for 12-60 hr).
Silver intensification of the immunogold labeling of the ENK-positive terminals was carried out (Chan et al., 1990; Mahalik, 1988) . The sections were rinsed in 0.1 M PB, then in 1% sodium acetate, and finally the gold was silver-intensified with the IntenSE kit (Amersham), incubating for 4, 6, or 8 min at RT (approximately 25°C).
After each labeling step, we examined some sections briefly at the LM level to determine if the labeljng procedure had been successful. Silverintensification labeling success was determined with darkfield illumination. Once the tissue had been successfully labeled with all three markers, we proceeded to the next step of embedding the tissue.
Tissue Preparation for EM. Sections were prepared for embedding in Spurr's resin by immersion for 10 min in each of a series of ethanol solutions: 50%, 70%, 80%, YO%, 95%, 100% ethanol. Thesectionswerestained for 1 hr in 1% uranyl acetate in 100% ethanol. They were rinsed in three changes of 100% ethanol, then infiltrated with Spurr's resin (Electron Microscopy Sciences; Fort Washington, PA) by immersion in the following:
(1) a 50:50 mixture of Spurr's resin and 100% ethanol, 4 hr; (b) 100% Spurr's resin, overnight; and (c) fresh 100% Spurr's resin, 2 hr. Infiltrated sections were mounted flat between glass slides and plastic coverslips (both coated with Liquid Release Agent from EMS) and cured. Pieces of embedded tissue were cut from the AVT or substantia nigra and mounted onto blocks, and ultra-thin sections were cut from the tissue surface with an ultramicrotome. These sections were mounted on mesh grids, stained with lead citrate and uranyl acetate (LKB Ultrostainer), and finally viewed and photographed with a JEOL 1200 or JEOL 2000 electron microscope.
Appearance of the Markers
At the LM level, many previous investigators have observed clear distinctions between the three markers we used in the present study, DAB, BDHC, and SIG. DAB reaction product is brown and diffusely fills the structures of interest (Chan et al., 1990; Levey et al., 1986; Van den Pol et al., 1985) . BDHC reaction product, in contrast, is blue and crystalline and the crystals are large enough to be evident as such in the labeled structures ( h e y et al., 1986). Silver-intensified immunogold is black, dense, and punctate at the LM level, thereby giving labeled structures a mottled appearance (Chan et al., 1990; Van den Pol et al., 1985) . After osmication, the three markers are all blackened and rendered much less distinguishable at the LM level. Nevertheless, all three markers were still very distinct at the EM level in our present study and in previous studies employing pairs of these markers (Anderson et al., 1991; Chan et al., 1990; Levey et al., 1986; Van den Pol et al., 1985) . At the EM level, DAB precipitate was dark and flocculent and filled the SP-positive terminals, consistent with its LM appearance. Also at the EM level, the BDHC labeling of TH-positive neurons and their dendrites consisted of discrete clumps of crystalline, typically elongate reaction product with a dark flocculent background. In many cases the BDHC reaction product extended outside of cell boundaries. However, the presence of a dark background enabled us to distinguish between labeled and unlabeled structures, and the presence of BDHC crystals allowed us to distinguish between DAB and BDHC labeling. At the EM level, SIG labeling appeared as black, nearly round particles. These profiles varied in size (approximately 25-100 nm) but were always smaller than BDHC granules, and no dark flocculent background was present in SIG-labeled structures. Although individual SIG particles sometimes overlaid structures other than terminals (perikarya, dendrites, glia), nonspecific background staining was sparse. Nevertheless, only terminals showing an appreciable accumulation of SIG particles (i.e., five or more) were considered to be ENK positive. The SIG-labeled terminals were of the same size and possessed the same morphological characteristics as ENKpositive terminals within the avian AVT and substantia nigra that we observed in a previous study using only DAB labeling techniques .
Relative Localization of SP-positive and ENK-positive Terminals on THpositive and Non-TH-positive Tegmental Neuron3
In a sample of sections taken from the AVT, many instances of labeled structures in apposition with each other were observed. We saw many SP-positive terminals on the TH-positive dendrites and on non-TH-positive dendrites, as well as many examples of ENKpositive terminals on both of these types of dendrites (Fig. 1) . These findings are consistent with our previous studies. In addition, we saw many instances of SP-positive terminals and ENK-positive terminals contacting the same individual dendrites (Fig. 2) . Since penetration of SP-positive DAB labeling and TH-positive BDHC labeling was comparable (up to ~1 0 pm in depth) and greater than that for ENK-positive SIG labeling (up to only ~4 pm in depth), the presence or absence of BDHC in structures contacted by both ENK-and SP-positive terminals indicated whether the postsynaptic structure was TH positive or not. Therefore, the many observed instances of SP-and ENK-positive terminals contacting a non-BDHC-labeled dendrite can be interpreted to represent instances of the SP-positive terminal and the ENK-positive terminal contacting the same non-TH-positive dendrite. In these cases we typically observed other dendrites surrounding the structure of interest and in the same field of view to be BDHC+/TH+, further supporting the notion that the non-BDHC-positive structure receiving input from the SP-and ENK-positive terminals was in fact non-TH-positive. In a few instances we observed SP-and ENK-positive terminals contacting the same TH-positive dendrite. However, in the limited sample examined to date, non-TH-positive dendrites far outnumbered TH-positive dendrites as the structure postsynaptic to combine SPand ENK-positive input (2 5 non-TH-positive dendrites compared with two TH-positive dendrites). In contrast, SP-positive terminals and ENK-positive terminals separately were distributed much more equally between TH-positive and non-TH-positive dendrites (18 ENK-positive terminals on non-TH-positive dendrites vs 13 ENKpositive terminals on TH-positive dendrites; 10 SP-positive terminals on non-TH-positive dendrites vs 22 SP-positive terminals on TH-positive dendrites).
Otber Sequences for Triple Labeling
We have presented this particular sequence of steps for carrying out triple labeling based on the results of our trial-and-error experiences with various other sequences. We carry out the PAPIBDHC labeling after completing the PAPIDAB labeling step because the BDHC label is much more labile than the DAB marker. Immersion of the BDHC-labeled tissue in a neutral or basic buffer rapidly converts the BDHC reaction product from its distinctive crystalline form to an appearance indistinguishable from that of DAB at both the LM and EM levels. To prevent inadvertent conversion of the BDHC reaction product to a DAB-type reaction product, we found it useful to osmicate immediately after the BDHC reaction. This stabilizes and prevents conversion of the BDHC reaction product. We have found, however, that osmication after silver intensification can dissolve the SIG label. To prevent such loss of SIG label, we found it desirable to osmicate and then silver intensify. However, we also found that silver intensification after osmication Figure 1 . SP' and ENK'terminals contact dopaminergic and nondopaminergic structures. (a) SP' terminal labeled with DAB makes a symmetric synapse with a non-dopaminergic dendritic shaft (U). Small BDHC-labeled structures were visible in the tissue surrounding the unlabeled shaft and indicated that the label had penetrated to this level, and therefore the target would be labeled if it were dopaminergic. One of these BDHC-labeled structures is visible in the lower center section of the figure. (b) SP' terminal labeled with DAB apposes a dopaminergic dendritic shaft labeled with BDHC. (c) ENK' terminal labeled with SIG apposes a large non-dopaminergic dendritic shaft (U). The presence of small BDHC-labeled structures in the tissue surrounding the shaft indicated that the label had penetrated to this level, and therefore the target would be labeled if it were dopaminergic. A small fragment of the BDHC labeling in one of the surrounding structures is visible in the lower right corner of the figure. (d) ENK' terminal labeled with SIG forms a symmetric synapse with a dopaminergic dendritic shaft labeled with BDHC. Bars = 0.5 pm.
. .. 14 -. I Figure 2 . SP' and ENK' terminals sometimes contact the same dopaminergic or non-dopaminergic structures. (a) SP* terminal labeled with DAB and ENK' terminal labeled with SIG form appositions (arrows) with a dopaminergic dendritic shaft labeled with BDHC. (b) SP' terminals labeled with DAB and ENK' terminals labeled with SIG form symmetric synapses and appositions with a non-dopaminergic dendritic shaft (U). EDHC in small structures in the surrounding tissue indicates the label has penetrated to this level, and therefore the target would be labeled if it were dopaminergic. The EDHC-labeled structures are not visible in this figure but were present in the tissue within the original field of view. Ears = 0.5 pm.
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sometimes results in some degradation of ultrastructural detail in some areas of the brain in some species. A higher than standard concentration of osmium (e.g., 3-4%) and a 1-2-hr duration osmication can be used to minimize such degradation in instances where it is otherwise consistently encountered in silver intensification after osmication. There was no evident loss of the immunogold label when the PAP/BDHC and osmication steps preceded the silverintensification step. The DAB label also appears very durable and therefore makes it possible to complete the PAP/DAB labeling first without' the concern that subsequent steps will diminish the DAB labeling. Finally, although we describe the use of only one set of primary antisera in the present study, other primary antiserum combinations for these same antigens can be used (e.g., antisera raised in different species than described here). Although we did try various other combinations-e.g., a rat monoclonal anti-SP (DAB), a mouse monoclonal anti-LENK (BDHC), and a rabbit polyclonal anti-TH (SIG)-such other combinations in our hands proved less effective for the triple labeling, in part because we tried to use BDHC labeling for ENK-positive terminals and BDHC crystals are too large to be ideal for unequivocally labeling terminals. In general, the antisera chosen should be those that most intensely label the target structures and they should be raised in a species compatible with the others that must be used.
Discussion
The present study has described an approach for carrying out preembedding triple-labeling EM immunohistmhemistry. We have also presented an example of how this approach can be applied to determine whether two different inputs (each containing a distinct antigen) contact the same postsynaptic target structure (containing a third antigen) within their common projection field. For example, we show that although both SP-positive and ENK-positive terminals can be simultaneously observed to contact the same THpositive dendrites in the AVT, they in fact most commonly converge on dendrites that do not contain TH (and are therefore nondopaminergic dendrites). There is no unequivocal method other than a triple-label immunohistochemical method (such as that described here) for evaluating such an issue. The method described is relatively simple to carry out, can yield very clear-cut and distinct labeling at the EM level of three different neural entities, and is therefore useful for addressing the type of issue described above. The method can be used to label neural structures based on their neurotransmitter content or the receptors present in their membranes, their intracellular messenger or enzyme content, their cytochemical constituents, or based on the introduction of some marker such as an anterograde or retrograde tracer (Bolam and Smith, 1992; Bras et al., 1991; Smith and Bolam, 1990) .
One limitation to the method is the availability of compatible sets of antisera for the purposes of the investigator, since the primaries must be raised in three different species and the secondaries must not crossreact with each other or with unintended primaries. Given the general availability of individual antisera raised in diverse species, this consideration should not be a major problem. A related problem is that for the effective use of this procedure we recommend a secondary conjugated to a 1-nm gold particle for the immunogold step, which is at present commercially available only for secondaries directed against immunoglobulins from a limited number of species. This, again, constrains the combinations of antisera that can be used. Nevertheless, we expect that this limitation can be readily overcome in most instances with a little forethought. For example, although a 1-nm gold-conjugated anti-rat secondary (Amersham) was not available at the time we did the studies described here, immunogold labeling could still be used for a primary raised in a rat host by using a rabbit anti-rat secondary antiserum, followed by a gold-conjugated anti-rabbit IgG (Amersham). We have, in fact, successfully used this approach in unpublished studies. Furthermore, the limitation in the availability of 1-nm gold-conjugated secondaries can be overcome by the investigator, if necessary, by having the required immunogold secondary custom made.
Comparzson with Other Multi)le-label Approaches
The other major EM immunohistochemical triple-label methods involve post-embedding labeling entirely (Doerr-Schott and Lichte, 1966; Varndell and Polak, 1984; Tapia et al., 1983) or involve some combination of pre-embedding and post-embedding staining (Bolam and Smith, 1992; Francois-Bellan and Bosler, 1992; Ribieroda-Silva et al., 1992; Groenewegen and Wouterlood, 1990; Smith and Bolam, 1990) . Post-embedding triple-label methods generally employ primary antisera raised in separate animal species and a set of secondary antisera each conjugated to different-sized gold particles, e.g., 5 nm, 10 nm, and 20 nm (Doerr-Schott and Lichte, 1986) . Triple labeling can also be achieved by pre-embedding DAB labeling for one antigen followed by post-embedding immunogold labeling for the other antigens with secondaries conjugated to two different-sized gold particles, one to mark a second antigen and another to mark a third. Alternatively, DAB and BDHC labeling can be used to label two separate antigens before embedding and immunogold labeling can be carried out after embedding (Bolam and Smith, 1991; Groenewegen and Wouterlood, 1990) , or DAB, BDHC, and tetramethylbenzidine (TMB) can all be combined in a pre-embedding labeling study (Smith and Bolam, 1990) . Finally, some studies have used EM autoradiographic labeling for one marker with pre-embedding immunohistochemical labeling (using DAB and BDHC) for the other two (Francois-Bellan and Bosler, 1992) . Any multiple-labeling method involving post-embedding staining as one of the steps has the serious disadvantage that osmication and embedding can greatly reduce antigenicity and make it difficult to detect the desired antigens (Doerr-Schott and Lichte, 1986; Varndell and Polak, 1984; Tapia et al., 1983) . For plentiful antigens this may not be a hindrance, but for less plentiful ones it is. Furthermore, it is laborious to process large amounts of tissue by post-embedding staining methods. Post-embedding staining with immunogold, however, has the advantage that penetration into the tissue is not the problem that it is with pre-embedding staining (Doerr-Schott and Lichte, 1986; Varndell and Polak, 1984; Tapia et al., 1983) . It is possible that some type of penetration-enhancing method such as freeze-thawing or saponin treatment might enhance penetration of the immunogold reagent during preembedding staining (Groenewegen and Wouterlood, 1990) , although the level of enhancement must be weighed against the deterioration of membranes resulting from these techniques. Never-theless, we found acceptable penetration of our 1-nm immunogold secondary without use of any penetration-enhancing methods. Therefore, it is clear that the triple-label pre-embedding EM immunohistochemical method described here is a useful procedure that can yield readily interpretable results and we believe that it should prove applicable for many neural systems.
